RELEVANT study: Patient and physician perspectives on clinically-meaningful outcomes in advanced pancreatic ductal adenocarcinoma
Mak, Soo Yit Gustin
Hubner, Richard A
Valle, Juan W
McNamara, Mairead G
AffiliationThe Christie NHS Foundation Trust/ The University of Manchester
MetadataShow full item record
AbstractBackground Little is known about patient/physician views on treatment decision-making, goals and clinically-meaningful outcomes in advanced PDAC. Method A prospective questionnaire study in consecutive patients with newly-diagnosed advanced PDAC and their physicians. Patients completed a study survey and 2 QOL questionnaires (EORTC QLQ-C30 and PAN26) at 3 timepoints: before starting chemotherapy(T1); before(T2) and after 1st on-treatment scan (T3); paired survey was completed by physician at each timepoint. Results Of 71 patients, median age 65y, 52% male, 93% stage III-IV, 76% ECOG 0-1. 32% started triplet chemotherapy, 38% dual and 23% monotherapy. 12 physicians participated; 65 patientand 70 physician T1-surveys completed. Chemotherapy adverse event acceptability was similar between patients and physicians (infection: least acceptable, rash: most acceptable). For patients, the most important aspect when selecting chemo was OS; physicians favoured OS/side-effect balance. Thirty-six(55%) patients had life goals and priorities; only 11% physicians knew of these. Patients and physicians ranked ability to self-care as main priority, and ability to work as least important. Patients also prioritised spending time with family (ranked 1 out of 7); this was less important for physicians. Most patients(75%) were aware that treatment was unlikely to cure their cancer. Physician responses(85%) expected chemo to extend life by 1-2 months or 3-6m; 11% of patients expected it to be 3-6m, and 51% expected 1-5 or >5years. Similarly, 37% patients answered that minimal meaningful extra time was 1-5 or >5years, while 73% of physicians thought this was 3-6m. 42% of patients were willing to have chemotherapy even with large number of side-effects; only 10% of physicians thought they would. Physicians underestimated how many patients would be willing to accept chemo if it controlled symptoms but did not extend survival (47% vs 63% respectively). Updated results will be presented. Conclusion While patients had realistic expectations about cure, they largely overestimated the expected life extension.
CitationPihlak R, Frizziero M, Mak S, Nuttall C, Lamarca A, Hubner R, et al. P-274 RELEVANT study: Patient and physician perspectives on clinically-meaningful outcomes in advanced pancreatic ductal adenocarcinoma. Annals of Oncology. 2020;31:S179.
JournalAnnals of Oncology
TypeMeetings and Proceedings